Certara Expands Presence in Drug Discovery and Development Markets in China and Taiwan

Tri-I Biotech, Inc. Named Area Distributor/Representative for Mainland Chinese and Taiwanese Customer Base

ST. LOUIS--(BUSINESS WIRE)--Certara™, a global, translational sciences company formed by the acquisition of Pharsight^® Corporation by Tripos™, today announced expanded investment and presence in China and Taiwan in support of drug discovery and development efforts, and also confirmed that Tri-I Biotech, Inc. has been selected as the sole distributor of the combined Certara offerings in the two countries.

“By combining Tripos’ and Pharsight’s powerful product and service offerings, Certara is uniquely positioned to bridge the translational pharmacology market space, offering solutions that begin in drug discovery and span clinical trials”

“We are very pleased with the selection of Tri-I Biotech as our partner in the strategic markets of mainland China and Taiwan,” said Patrick Flanagan, Chief Operating Officer for Certara. “Working with Tri-I, pharmaceutical and biotech drug discovery and development organizations will have easy access to Certara’s tools, training and support. This will enable the research community to more effectively analyze, interpret, and share data and key information. Tri-I is an important part of the Certara service and support strategy, and they will provide drug discovery and development scientists within mainland China and Taiwan with full access to Certara’s wide range of new software solutions, as well as new releases of existing products.”

“By combining Tripos’ and Pharsight’s powerful product and service offerings, Certara is uniquely positioned to bridge the translational pharmacology market space, offering solutions that begin in drug discovery and span clinical trials,” said Steve Hsu, President of Tri-I Biotech. “We are very pleased to be the partner of choice for Certara, and to help clients in mainland China and Taiwan propel their research efforts forward using these important technologies.”

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos and Pharsight Corporation. Tripos is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight is the leading provider of software and scientific services to improve productivity and decision-making in clinical drug development. Certara expects to provide its clients with important new products, key enabling technologies and scientific expertise to expedite the flow of information throughout drug discovery and development. Certara is focused on reducing the barriers between the phases of research that will speed discoveries in chemistry and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5996958&lang=en